@cantab, @karen1945 & @vic83 - There are a lot of issues with the pharmaceutical companies and how drugs (prescription & over the counter) are promoted.
But, there is an UP side as well - the deep pockets allow research that would never otherwise occur. I know the motives is profit, but my niece (a research nurse specializing in post-stroke recovery) tells me at least 50-100 ideas are discarded for every one that becomes a marketable product. So....?
Also, there are efforts to rein in the freebies and resulting over-prescription. The large clinical/hospital practice where I am a patient only allows pharma reps to approach a specific team in the organization. All literature and samples are given to them for evaluation, if they pass muster, the care team gets them. There are NO freebies - lunches, trips, etc - for the team or any employee. My ortho practice has the same policy. As a result, we are not constantly prescribed newer, "better" & more expensive drugs. As a matter of fact, I often learn about them on Mayo Connect or from others, and ask my docs about them! Some state legislatures have also taken steps to limit the drug (and medical appliance) promos, as have some medical associations.
It pays to be a cautious consumer when new meds are prescribed "Is there something else I can try first? Like physical therapy, diet, exercise or a supplement?" "Why is this better than the old one?" How long has it been around?" Is there a generic alternative?"
I just submitted this question, regarding statins, to my primary when I felt like I was being pushed by a cardiologist who is new to me.
Have any of you asked your care providers for a non-prescription alternative treatment?
Sue
Glad to hear that there is an effort to limit the promotional push of drug companies. Healthcare industries were end markets in my job, so I did a lot of research on them. Drug companies would investigate other treatments for each of their targeted markets, because competition comes not only from another drug company, but also from new technologies that would take market share away from a standard drug therapy. But for rare diseases with insignificant markets, I would not expect any kind of investment from a drug company.... they have to answer to the shareholders who don't buy stock for charity.
It is also interesting to look at what happens when a drug comes off patent. To keep a drug under patent, they sometimes make a tweak or change in the manufacturing process.